Below is a statement from Bristol-Meyers Squibb regarding Kenalog:
"Kenalog-10 is suitable for intralesional and intra-articular injection only. Kenalog-40 is suitable for intramuscular and intra-articular injection only. These are the only routes of administration that have been in the label for these products since their initial approvals. During post-marketing safety surveillance, adverse events related to epidural administration were identified. This prompted the company to submit revised safety language to the US Food and Drug Administration stating in the warnings section that 'Epidural and intrathecal administration of this product is not recommended.' The FDA approved the updated label for Kenalog in June 2011. The company subsequently updated the prescribing information included with Kenalog and posted the new prescribing information on our website. The FDA also updated its website with the new prescribing information and included it in MedWatch: The Safety Information and Adverse Event Reporting Program."